食管鳞状细胞癌中SNORA71B的表达及其与临床病理特征的关系

Expression of SNORA71B in esophageal squamous cell carcinoma and its relationship with clinicopathological features

目的探讨核仁小RNA 71B(SNORA71B)基因在食管鳞状细胞癌(esophageal squamous cell cancer,ESCC)组织和细胞株中的表达及与临床病理特征的关系。方法应用qRT-PCR法检测ESCC组织和癌旁正常组织中SNORA71B基因的表达,分析其表达与ESCC临床病理特征及预后的关系;应用shRNA瞬时转染食管癌细胞株Eca109干扰SNORA71B基因的表达,采用MTS和Transwell实验检测SNORA71B基因异常表达对食管癌细胞Eca109增殖和侵袭的影响。结果SNORA71B基因在ESCC组织中的表达(3.242±1.074)明显高于癌旁正常组织(1.212±0.470,P<0.05),其与淋巴结转移、分化程度、浸润深度和TNM分期密切相关(P均<0.05);其与生存期密切相关(高表达组12.3%vs低表达组25.7%,P<0.01),可作为ESCC患者独立的预后因素(P<0.01)。敲低SNORA71B基因可抑制ESCC细胞系Eca109的体外增殖能力和侵袭能力(P<0.05)。结论SNORA71B基因在ESCC中可能发挥癌基因的作用,其高表达可能促进ESCC细胞的增殖和侵袭,有望成为ESCC患者预后评估的生物学标志物。

Purpose To investigate the gene expression of small nucleolar RNA 71B(SNORA71B)in esophageal squamous cell carcinoma(ESCC)tissues and cell lines and its relationship with clinicopathological features.Methods The expression of SNORA71B gene in ESCC and adjacent normal tissues was detected by qRT-PCR,and the relationship between its expression and clinicopathological features and prognosis of ESCC patients was analyzed,shRNA was transiently transfected into Eca109 cell line to interfere with SNORA71B expression.The cell proliferation and invasion of Eca109 cells were detected by MTS and Transwell experiments.Results The expression of SNORA71B in ESCC tissues(3.242±1.074)was significantly higher than that in adjacent normal tissues(1.212±0.470,P<0.05).Upregulated SNORA71B expression was related to lymph node metastasis,degree of differentiation,depth of invasion and TNM stage(P<0.05).It also was closely related to survival(12.3%in high expression group vs 25.7%in low expression group,P<0.01),and SNORA71B expression was significantly associated with poorer survival,which would help to identify high-risk patients(P<0.01).SNORA71B knockdown inhibited the proliferation and invasion of Eca109 in vitro(P<0.05).Conclusion SNORA71B may play an oncogene role in ESCC,and its high expression may promote the proliferation and invasion of ESCC cells.SNORA71B is expected to be a biomarker for the prognosis evaluation of ESCC patients.